Drug treatment of diabetic retinopathy on stages of its development (problems, doubts, solutions)
Despite significant progress in the treatment of diabetic retinopathy, this disease consistently occupies the 2 or 3 place for reasons of disability of the organ of vision. Ophthalmic treatments, including timely laser coagulation of the retina, correct anti-VEGF therapy are defi nitely successful. However, timely and comprehensive drug treatment for diabetic retinopathy is required at all stages of the development of this pathology. With the advancement in the study of pathogenesis of diabetic retinopathy and the success of pharmacy the guidelines for pharmacotherapy were defi ned, which include correct glycemic control, aldose reductase inhibitors, antagonists of AT1-receptors, ACE inhibitors, Omega-3 fatty acids, antioxidants and a variety of other drugs. Ophthalmologists pay particular attention to fenofibrate, which gives new possibilities in the treatment of diabetic retinopathy due to its pleiotropic effect, including anti-VEGF effect. Thanks to its pharmacological effects, the use of fenofibrate is required at all stages of the development of diabetic retinopathy.